biotechradar.eu

Business Intelligence on European listed biotech companies
Status: Inactive from 30-06-2023

[biotechradar.eu @biotechradar_eu]

Orexo $ORX wins patent litigation for ZUBSOLV in the US
https://t.co/SwZ6h3j7MN

[biotechradar.eu @biotechradar_eu]

Zealand Pharma $ZEAL submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism https://t.co/VvGqNolsS9

[biotechradar.eu @biotechradar_eu]

argenx $ARGX and Zai Lab $ZLAB Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China https://t.co/Lg6VY7SlbQ

[biotechradar.eu @biotechradar_eu]

BioSenic $BIOS provides financial update https://t.co/mh4bbe5PFA

[biotechradar.eu @biotechradar_eu]

Ipsen $IPN and GENFIT $GNFT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease https://t.co/xraSUHGkyb

[biotechradar.eu @biotechradar_eu]

NFL BIOSCIENCES $ALNFL GB HOLDING TAKES A STAKE IN THE COMPANY’S CAPITAL UPON THE EXERCISE OF SHARE SUBSCRIPTION WARRANTS AND PAYMENT OF 0.5M€, AND ALSO COMMITS TO A LOCK-UP https://t.co/ivSG5BizLU

[biotechradar.eu @biotechradar_eu]

Egetis $EGTX announces site activation in the pivotal ReTRIACt trial for Emcitate and updates timeline for the US NDA submission
https://t.co/DtKwp5K46A

Initiator Pharma $INIT completes recruitment in Phase IIb trial with pudafensine (IP2015)
https://t.co/TANnhgfAr3

[biotechradar.eu @biotechradar_eu]

Diamyd Medical $DMYDB announces final outcome in the company's rights issue
https://t.co/Uo01bWchn8

CombiGene $COMBI forms prominent Scientific Advisory Board within the pain program COZY
https://t.co/nzai7lgxUt

[biotechradar.eu @biotechradar_eu]

Destiny Pharma $DEST Business Update
https://t.co/pqPa2eHNcw

Poolbeg Pharma $POLB AI led programme identifies influenza drug targets
https://t.co/bMtagGxCcQ

Faron $FARN Announcement of Placing
https://t.co/thpgJIAbrT

[biotechradar.eu @biotechradar_eu]

Cosmo $COPN announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia
https://t.co/SgWzG9ReNM

[biotechradar.eu @biotechradar_eu]

Heidelberg Pharma $HPHA Sells Minority Shareholding in Emergence Therapeutics https://t.co/QlJW08kUmM

[biotechradar.eu @biotechradar_eu]

Formycon $FYB announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. FDA https://t.co/hOePDjr19B

[biotechradar.eu @biotechradar_eu]

Evotec $EVT $EVO receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme https://t.co/h79SSaikIi

[biotechradar.eu @biotechradar_eu]

Santhera $SANN Publishes Timeline of the Reverse Share Split https://t.co/T2bJKOyL1l

[biotechradar.eu @biotechradar_eu]

Alvotech $ALVO Provides Regulatory Update on Second Biologics License Application for AVT02 https://t.co/qd2TJjUjUu

[biotechradar.eu @biotechradar_eu]

Nordic Nanovector $NANOV - Appointment of Alf Bjørseth as CEO https://t.co/uesQgFfjI2

[biotechradar.eu @biotechradar_eu]

Ultimovacs $ULTI Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results https://t.co/lKgZmMGST2

[biotechradar.eu @biotechradar_eu]

Lipigon $LPGO receives Vinnova grant for larger EU application for Lipisense against severe hypertriglyceridemia
https://t.co/vgcFlbxjii

$Xspray raises approximately SEK 251 million through a rights issue
https://t.co/Oy0yOa51ZE

[biotechradar.eu @biotechradar_eu]

Abliva $ABLI announces first patient dosed in the FALCON study
https://t.co/2rpPDuKVX2

Diamyd Medical $DMYDB announces preliminary outcome in the company's rights issue
https://t.co/RXAbuqtpCw

Diamyd $DMYDB Quarterly Report III 22/23
https://t.co/ExH6qygtVp

[biotechradar.eu @biotechradar_eu]

Philogen $PHIL enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein https://t.co/vtLZWNnZPk